TACSTD2 and neoplasm: While TROP2 expression was moderate to strong in TER-MET(-R) and absent in normal testicular tissue, supporting its tumor specificity and potentially favorable safety profile, TER is typically a differentiated, non-proliferative component of non-seminomatous GCT and is inherently resistant to standard chemotherapy (Singla et al. 2025).